Signaturefd LLC Sells 7,417 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Signaturefd LLC reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 91.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 690 shares of the biotechnology company's stock after selling 7,417 shares during the period. Signaturefd LLC's holdings in Sarepta Therapeutics were worth $84,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Louisiana State Employees Retirement System raised its position in shares of Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after buying an additional 100 shares in the last quarter. Manchester Capital Management LLC raised its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 138 shares during the period. CIBC Asset Management Inc grew its holdings in shares of Sarepta Therapeutics by 5.1% during the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after purchasing an additional 139 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock worth $352,000 after purchasing an additional 145 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Remove Ads

Sarepta Therapeutics Trading Down 3.6 %

Shares of NASDAQ:SRPT traded down $2.72 during mid-day trading on Tuesday, hitting $73.61. The company had a trading volume of 1,303,489 shares, compared to its average volume of 1,223,667. The company has a market capitalization of $7.14 billion, a PE ratio of 58.89 and a beta of 0.79. Sarepta Therapeutics, Inc. has a one year low of $73.05 and a one year high of $173.25. The firm has a fifty day moving average price of $106.35 and a 200 day moving average price of $117.47. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 7.70% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SRPT. HC Wainwright reiterated a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, March 19th. Scotiabank reduced their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research note on Thursday, March 20th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $167.41.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.